Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
May 15 AEZS Aeterna Zentaris GAAP EPS of -$4.74
May 15 AEZS MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden
May 14 AEZS Aeterna Zentaris Reports First Quarter 2024 Financial Results
May 14 AMGN Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)
May 14 AYTU Aytu BioScience Q3 Earnings Preview
May 14 AFMD Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
May 14 AFMD Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
May 14 EPIX ESSA Pharma GAAP EPS of -$0.20 misses by $0.01
May 14 EPIX ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
May 14 BNR Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
May 13 CRDF Cardiff Oncology to Present at Upcoming Investor Conferences in May
May 13 AMGN The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs
May 12 EXEL Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
May 12 AMGN Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
May 11 EXEL Exelixis files patent suit against India’s Cipla over Cabometyx generics
May 11 AMGN We Wouldn't Be Too Quick To Buy Amgen Inc. (NASDAQ:AMGN) Before It Goes Ex-Dividend
May 10 AMGN 5 Stocks Driving Dow's Market-Beating Performance
May 10 EDAP EDAP TMS S.A.'s (NASDAQ:EDAP) top owners are individual investors with 56% stake, while 24% is held by institutions
May 9 AMGN AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
May 9 AMGN CytomX slides after early data for Amgen-partnered cancer drug
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags